Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Lucas F, Mata DA, Greenblatt MB, Means J, Jarolim P. A Potassium-Based Quality-of-Service Metric Reduces Phlebotomy Errors, Resulting in Improved Patient Safety and Decreased Cost. Am J Clin Pathol. 2022;157(5):789-798.

Gulve N, Su C, Deng Z, Soldan SS, Vladimirova O, Wickramasinghe J, et al. DAXX-ATRX regulation of p53 chromatin binding and DNA damage response. Nat Commun. 2022;13(1):5033.

Adhikari S, Guha D, Mohan C, Mukherjee S, Tyler JK, Das C. Reprogramming Carbohydrate Metabolism in Cancer and Its Role in Regulating the Tumor Microenvironment. Subcell Biochem. 2022;100:3-65.

Suryawanshi H, Yang H, Lubetzky M, Morozov P, Lagman M, Thareja G, et al. Detection of infiltrating fibroblasts by single-cell transcriptomics in human kidney allografts. PLoS One. 2022;17(6):e0267704.

Rosenthal J, Carelli R, Omar M, Brundage D, Halbert E, Nyman J, et al. Building Tools for Machine Learning and Artificial Intelligence in Cancer Research: Best Practices and a Case Study with the PathML Toolkit for Computational Pathology. Mol Cancer Res. 2022;20(2):202-206.

Chen J, San SS, Kung A, Tomasek M, Liu D, Rodgers W, et al. Direct-from-specimen microbial growth inhibition spectrums under antibiotic exposure and comparison to conventional antimicrobial susceptibility testing. PLoS One. 2022;17(2):e0263868.

Orea-Soufi A, Paik J, Bragança J, Donlon TA, Willcox BJ, Link W. FOXO transcription factors as therapeutic targets in human diseases. Trends Pharmacol Sci. 2022;43(12):1070-1084.

van der Mijn JC, Eng KW, Chandra P, Fernandez E, Ramazanoglu S, Sigaras A, et al. The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Mol Oncol. 2022;16(12):2384-2395.

Magro C, Grossman ME, Karaaslan S, Skrokov R, Valinotti M. Localized pemphigus vegetans of the nose and lips: A classic case of a rare entity. JAAD Case Rep. 2022;25:67-71.

Burns D, Anokian E, Saunders EJ, Bristow RG, Fraser M, Reimand J, et al. Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. Eur Urol. 2022;82(2):201-211.